Literature DB >> 7016483

Azathioprine and 6-mercaptopurine have a role in the treatment of Crohn's disease.

J E Lennard-Jones.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1981        PMID： 7016483     DOI： 10.1007/bf01308381

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN： 0163-2116            Impact factor:   3.199


× No keyword cloud information.
  13 in total

1.  Treatment of Crohn's disease with azathioprine: a controlled evaluation.

Authors:  M Klein; H J Binder; M Mitchell; R Aaronson; H Spiro
Journal:  Gastroenterology       Date:  1974-05       Impact factor: 22.682

2.  Controlled trial of azathioprine in Crohn's disease.

Authors:  J M Willoughby; J Beckett; P J Kumar; A M Dawson
Journal:  Lancet       Date:  1971-10-30       Impact factor: 79.321

3.  Azathioprine for Crohn's disease.

Authors:  B N Brooke; D C Hoffmann; E T Swarbrick
Journal:  Lancet       Date:  1969-09-20       Impact factor: 79.321

4.  Controlled trial of azathioprine in Crohn's disease.

Authors:  J Rhodes; D Bainton; P Beck; H Campbell
Journal:  Lancet       Date:  1971-12-11       Impact factor: 79.321

5.  Place of azathioprine for Crohn's disease.

Authors:  B N Brooke; D R Cave; D W King
Journal:  Lancet       Date:  1976-05-15       Impact factor: 79.321

6.  National Cooperative Crohn's Disease Study: results of drug treatment.

Authors:  R W Summers; D M Switz; J T Sessions; J M Becktel; W R Best; F Kern; J W Singleton
Journal:  Gastroenterology       Date:  1979-10       Impact factor: 22.682

7.  Azathioprine in ulcerative colitis: final report on controlled therapeutic trial.

Authors:  D P Jewell; S C Truelove
Journal:  Br Med J       Date:  1974-12-14

8.  Double-blind withdrawal trial of azathioprine as maintenance treatment for Crohn's disease.

Authors:  D P O'Donoghue; A M Dawson; J Powell-Tuck; R L Bown; J E Lennard-Jones
Journal:  Lancet       Date:  1978-11-04       Impact factor: 79.321

9.  Collaborative United Kingdom-Australasian study of cancer in patients treated with immunosuppressive drugs.

Authors:  L J Kinlen; A G Sheil; J Peto; R Doll
Journal:  Br Med J       Date:  1979-12-08

10.  Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study.

Authors:  D H Present; B I Korelitz; N Wisch; J L Glass; D B Sachar; B S Pasternack
Journal:  N Engl J Med       Date:  1980-05-01       Impact factor: 91.245
View more
  6 in total

1.  Immunopathology of ulcerative colitis and Crohn's disease, nonsurgical therapeutic considerations.

Authors:  F Bläker; K H Schäfer
Journal:  Eur J Pediatr       Date:  1982-11       Impact factor: 3.183

Review 2.  Toward optimal use of corticosteroids in ulcerative colitis and Crohn's disease.

Authors:  J E Lennard-Jones
Journal:  Gut       Date:  1983-03       Impact factor: 23.059

Review 3.  Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease.

Authors:  Nilesh Chande; Cassandra M Townsend; Claire E Parker; John K MacDonald
Journal:  Cochrane Database Syst Rev       Date:  2016-10-26

Review 4.  Inflammatory bowel disease.

Authors:  G M Van Rosendaal
Journal:  CMAJ       Date:  1989-07-15       Impact factor: 8.262

5.  6-Mercaptopurine-related pancreatitis in 2 patients with inflammatory bowel disease.

Authors:  L Bank; J P Wright
Journal:  Dig Dis Sci       Date:  1984-04       Impact factor: 3.199

6.  Exome sequencing and array-based comparative genomic hybridisation analysis of preferential 6-methylmercaptopurine producers.

Authors:  E W Chua; S Cree; M L Barclay; K Doudney; K Lehnert; A Aitchison; M A Kennedy
Journal:  Pharmacogenomics J       Date:  2015-03-10       Impact factor: 3.550
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.